Men's Sexual Health Consult Collection: Testosterone Replacement Therapy in the VA Setting CME

Author Information and Disclosures

Release Date: June 27, 2008; Valid for credit through June 27, 2009

Credits Available
Physicians - maximum of 1.25 AMA PRA Category 1 Credit(s)™ for physicians

This activity was created for distribution on Medscape.

To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details.

Contents of This CME Activity

  1. IntroductionJames V. Felicetta, MD
  2. Diagnosis and Evaluation of Male HypogonadismAlvin M. Matsumoto, MD
  3. Options in Testosterone Replacement TherapyAdrian Dobs, MD; Diala El-Maouche, MD
  4. Potential Adverse Effects of TRTGlenn R. Cunningham, MD; Sumbul Beg, MD; Lara Al-Khoury Nabbout, MD

Legal Disclaimer

The material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

Copyright © 2008 Quadrant Medical Education.
Solvay
Learning Objectives

Upon completion of this activity, participants will be able to:

  1. Recall at least three conditions common among VA patients that are closely associated with adult-onset hypogonadism
  2. Identify five adverse symptoms associated with adult-onset hypogonadism that testosterone replacement therapy (TRT) has been shown to ameliorate
  3. Describe four clear indications for TRT in adult males
  4. Discuss current recommendations regarding pretreatment screening and post-treatment monitoring of TRT
Authors and Disclosures

Lara Al-Khoury Nabbout, MD
Disclosure: Dr. Nabbout reports no actual or potential conflicts of interest in relation to this article.


Sumbul Beg, MD
Disclosure: Dr. Beg reports no actual or potential conflicts of interest in relation to this article.


Glenn R. Cunningham, MD
Disclosure: Dr. Cunningham: Contracted Research: Ardana, Ascend, GlaxoSmithKline; Solvay Pharmaceuticals. Consultant: Indevus Pharmaceuticals, Inc.; Solvay Pharmaceuticals. Speakers’ Bureau: Indevus Pharmaceuticals, Inc.; Solvay Pharmaceuticals.


Adrian S. Dobs, MD
Disclosure: Dr. Dobs: Contracted Research: Ardana; Indevus Pharmaceuticals, Inc; ProStrakan.


Diala El-Maouche, MD
Disclosure: Dr. El-Maouche reports no actual or potential conflicts of interest in relation to this article.


James V. Felicetta, MD, Chair
Disclosure: Dr. Felicetta reports no actual or potential conflicts of interest in relation to this article.


Alvin M. Matsumoto, MD
Disclosure: Dr. Matsumoto: Contracted Research: Ardana; Ascend; GlaxoSmithKline; Solvay Pharmaceuticals. Consultant: Amgen; GlaxoSmithKline; GTx, Inc.; QuatRx Pharmaceuticals Company; Solvay Pharmaceuticals.
 
Postgraduate Institute for Medicine
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Postgraduate Institute for Medicine (PIM) and Quadrant Medical Education. PIM is accredited by the ACCME to provide continuing medical education for physicians.

Postgraduate Institute for Medicine designates this educational activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Contact This Provider

All material on this website is protected by copyright, Copyright © 1994-2008 by Medscape. This website also contains material copyrighted by 3rd parties.